Current clinical studies are investigating new therapy options for melanoma patients with brain metastases such as PD-1 antibodies, ipilimumab plus nivolumab, BRAF inhibitors plus MEK inhibitors, as well as stereotactic radiotherapy in combination with immunotherapy or targeted therapy [48]. The gene discussed is PDCD1; the disease is melanoma.